The novel approach of radioligand therapy (RLT) is transforming patient identification and cancer treatment
See how RLT unites the precision of targeted therapy with systemic anti-tumor activity to destroy cancer cells while potentially minimizing damage to healthy cells1,2
RLT combines a targeting compound, a ligand that binds to a specific marker, and a radioisotope2,3
Click the labels to learn more about the components of radioligand therapy
RLT offers a novel way to mix and match isotopes and ligands to potentially help diagnose, monitor, and treat many types of cancers.1,3
References: 1. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589-608. doi:10.1038/s41573-020-0073-9 2. Ninatti G, Lee ST, Scott AM. Radioligand therapy in cancer management: a global perspective. Cancers. 2025;17:3412. doi:10.3390/cancers17213412 3. Holik HA, Ibrahim FM, Elaine AA, Putra BD, Achmad A, Kartamihardja AHS. The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker. Molecules. 2022;27:3062. doi:10.3390/molecules27103062 4. Duan H, Iagaru A, Aparici CM. Radiotheranostics—precision medicine in nuclear medicine and molecular imaging. Nanotheranostics. 2022;6(1):103-117. doi:10.7150/ntno.64141 5. Wadsley J, Flux G. Molecular radiotherapy comes of age. Clin Oncol. 2021;33:65-67. doi:10.1016/j.clon.2020.12.004 6. Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci. 2023;24:11626. doi:10.3390/ijms241411626